Suppr超能文献

人类结直肠癌中的三种 DNA 甲基化表型。

Three DNA methylation epigenotypes in human colorectal cancer.

机构信息

Genome Science Division, Department of Gastrointestinal Surgery, Research Center for Advanced Science and Technology, Translational Systems Biology and Medicine Initiative, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

出版信息

Clin Cancer Res. 2010 Jan 1;16(1):21-33. doi: 10.1158/1078-0432.CCR-09-2006. Epub 2009 Dec 22.

Abstract

PURPOSE

Whereas the CpG island methylator phenotype (CIMP) in colorectal cancer associates with microsatellite instability (MSI)-high and BRAF-mutation(+), the existence of an intermediate-methylation subgroup associated with KRAS-mutation(+) is controversial, and suitable markers for the subgroup have yet to be developed. Our aim is to clarify DNA methylation epigenotypes of colorectal cancer more comprehensively.

EXPERIMENTAL DESIGN

To select new methylation markers on a genome-wide scale, we did methylated DNA immunoprecipitation-on-chip analysis of colorectal cancer cell lines and re-expression array analysis by 5-aza-2'-deoxycytidine/Trichostatin A treatment. Methylation levels were analyzed quantitatively in 149 colorectal cancer samples using matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry. Colorectal cancer was epigenotyped by unsupervised two-way hierarchical clustering method.

RESULTS

Among 1,311 candidate silencing genes, 44 new markers were selected and underwent quantitative methylation analysis in colorectal cancer samples together with 16 previously reported markers. Colorectal cancer was clustered into high-, intermediate-, and low-methylation epigenotypes. Methylation markers were clustered into two major groups: group 1 showing methylation in high-methylation epigenotype, and group 2 showing methylation in high- and intermediate-methylation epigenotypes. A two-step marker panel deciding epigenotypes was developed with 95% accuracy: the 1st panel consisting of three group-1 markers (CACNA1G, LOX, SLC30A10) to extract high-methylation epigenotype, and the 2nd panel consisting of four group-2 markers (ELMO1, FBN2, THBD, HAND1) and SLC30A10 again to divide the remains into intermediate- and low-methylation epigenotypes. The high-methylation epigenotype correlated significantly with MSI-high and BRAF-mutation(+) in concordance with reported CIMP. Intermediate-epigenotype significantly correlated with KRAS-mutation(+). KRAS-mutation(+) colorectal cancer with intermediate-methylation epigenotype showed significantly worse prognosis.

CONCLUSIONS

Three methylation epigenotypes exist in colorectal cancer, and suitable classification markers have been developed. Intermediate-methylation epigenotype with KRAS-mutation(+) correlated with worse prognosis.

摘要

目的

结直肠癌的 CpG 岛甲基化表型(CIMP)与微卫星不稳定(MSI)高和 BRAF 突变(+)相关,而与 KRAS 突变(+)相关的中间甲基化亚组的存在存在争议,并且尚未开发出适合该亚组的标记物。我们的目的是更全面地阐明结直肠癌的 DNA 甲基化表型。

实验设计

为了在全基因组范围内选择新的甲基化标记物,我们对结直肠癌细胞系进行了甲基化 DNA 免疫沉淀芯片分析,并通过 5-氮杂-2'-脱氧胞苷/曲古抑菌素 A 处理进行了再表达阵列分析。使用基质辅助激光解吸/离子化-飞行时间质谱法在 149 例结直肠癌样本中定量分析了甲基化水平。通过无监督的双向层次聚类方法对结直肠癌进行了表观基因分型。

结果

在 1311 个候选沉默基因中,选择了 44 个新标记物,并与 16 个先前报道的标记物一起在结直肠癌样本中进行了定量甲基化分析。结直肠癌被聚类为高、中、低甲基化表型。甲基化标记物被聚类为两个主要组:组 1 显示在高甲基化表型中存在甲基化,组 2 显示在高和中甲基化表型中存在甲基化。开发了一个具有 95%准确性的两步标记面板来决定表观基因分型:第 1 组由三个组 1 标记物(CACNA1G、LOX、SLC30A10)组成,用于提取高甲基化表型,第 2 组由四个组 2 标记物(ELMO1、FBN2、THBD、HAND1)和 SLC30A10 组成,用于将剩余部分分为中低甲基化表型。高甲基化表型与报道的 CIMP 中的 MSI 高和 BRAF 突变(+)显著相关。中间表型与 KRAS 突变(+)显著相关。具有中间甲基化表型的 KRAS 突变(+)结直肠癌的预后明显较差。

结论

结直肠癌存在三种甲基化表型,并已开发出合适的分类标记物。与 KRAS 突变(+)相关的中间甲基化表型与较差的预后相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验